论文部分内容阅读
目的:分析鲍曼不动杆菌(Ab)的耐药性情况及多重耐药鲍曼不动杆菌(MDRAB)感染的治疗方案,探讨应对策略。方法:通过对惠州市中心人民医院自2014年1月至2015年12月住院部送检的216株鲍曼不动杆菌药敏测定的结果进行分析,结合其中78株多重耐药鲍曼不动杆菌感染的治疗方案,探讨多重耐药鲍曼不动杆菌感染的最佳应对策略。结果:在送检的216株鲍曼不动杆菌中,对米诺环素的敏感率最高,为89.35%;对头孢唑啉的敏感率最低,为4.17%。多重耐药鲍曼不动杆菌感染的治疗方案中,A组的头孢哌酮/舒巴坦+米诺环素和B组的哌拉西林/舒巴坦+左氧氟沙星效果较明显,优于其它组,差异具有统计学意义(P<0.05)。结论:鲍曼不动杆菌的耐药率正在逐年增长,临床医生应尽量根据患者的药敏试验结果选用抗菌药物,头孢哌酮,舒巴坦联合米诺环素和哌拉西林,舒巴坦联合左氧氟沙星可优先的选择。
OBJECTIVE: To analyze the drug resistance of Acinetobacter baumannii (AB) and the treatment plan of multidrug-resistant Acinetobacter baumannii (MDRAB) infection and to explore the coping strategies. Methods: Based on the results of 216 susceptible strains of Acinetobacter baumannii from the inpatient department of Huizhou Central People’s Hospital from January 2014 to December 2015, 78 strains of multidrug-resistant Acinetobacter baumannii Bacilli infection treatment programs to explore the multi-drug resistant Acinetobacter baumannii infection best coping strategies. Results: Among the 216 strains of Acinetobacter baumannii, the sensitivity to minocycline was the highest (89.35%) and the lowest to cefazolin (4.17%). Among the multiple drug-resistant Acinetobacter baumannii infections, cefoperazone / sulbactam + minocycline in group A and piperacillin / sulbactam + levofloxacin in group B were more effective than those in other groups , The difference was statistically significant (P <0.05). Conclusion: Acinetobacter baumannii resistance rate is increasing year by year, clinicians should try their best to choose antimicrobial agents, cefoperazone, sulbactam combined with minocycline and piperacillin, sulbactam Levofloxacin combined with the preferred choice.